Surefire Medical has announced that the company’s new Precision targeted delivery infusion system, for direct-to-tumour embolization procedures, has received the CE mark from European regulators. Surefire infusion systems are today used primarily in treating inoperable liver cancers, although clinical trials are under way for additional medical conditions.
“This product with its improved trackability will enable significant growth opportunities for Surefire Medical in the large worldwide primary liver cancer market,” said president and CEO James E Chomas. “The rapidly growing body of clinical evidence indicates greater drug penetration into tumours with the unique Surefire infusion systems, which addresses a clear need in a treatment of primary liver cancer that can bridge patients to a liver transplant or extend their life by suppressing tumour growth.”
A press release from the company states that the value of the primary hepatocellular cancer (HCC) market is set to grow by 172% by 2019, according to independent analyst firm Datamonitor Healthcare.
It further adds that HCC is the most common form of liver cancer, accounting for 83% of total liver cancer incidence. With approximately 80% of liver cancers being inoperable, today many patients are treated with a minimally invasive embolization procedure performed by an interventional radiologist.
